Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 19:7. Implied volatility suggests the market is ...
Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone ...
Highlights,Capricor Therapeutics is a biotechnology company specializing in the development of treatments for rare disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback